BloodStream Medicaid Cuts and vWD Clinical Trials
May 9, 2025
Join Benny Sorensen, CEO of Hemab, as he discusses groundbreaking clinical trials for von Willebrand’s disease and the potential impact of looming Medicaid cuts on the bleeding disorders community. Kayla Klein shares her heartfelt family story of resilience through hemophilia, alongside her mother, Nancy Rodgers, who recounts her experiences during the blood contamination crisis. Their powerful narratives highlight the importance of advocacy and community support in navigating the complexities of rare bleeding disorders.
AI Snips
Chapters
Transcript
Episode notes
Medicaid's Crucial Role for Patients
- Medicaid covers treatment for about one-third of the bleeding disorders community in the U.S.
- Cuts to Medicaid funding risk losing access and increasing preventable complications.
Advocate to Protect Medicaid Funding
- Call or email your lawmakers to oppose Medicaid funding cuts affecting bleeding disorders care.
- Use provided scripts and contact information, including the Capitol switchboard at 202.224.3121.
Hemab's Unique Mission
- Hemab focuses on bleeding disorders often neglected by biotech advances like glanzmann's and von Willebrand disease.
- Their mission is to build the ultimate clotting therapy company addressing unmet needs.